Alectinib shows benefit across genetic profiles in resected ALK-positive NSCLC
New data from the ALINA study confirm lack of influence of EML4-ALK variant on outcome in this patient population
New insights into pleural mesothelioma
Studies reveal promising evidence for the more precise tailoring of immunotherapy and the role of AI in improving response evaluation
Liquid biopsy plays a growing role in early-stage lung cancer
Research is moving forward to understand the value of this blood-based technology as a prognostic tool
Study findings confirm the benefits of BRAF and MEK inhibitors in mutated non-small cell lung cancer
Longer duration of efficacy reported for encorafenib plus binimetinib as a treatment for NSCLC harbouring a BRAF V600 mutation
New data add to current knowledge on how to optimise treatment in EGFR-mutant NSCLC
The use of targeted agents in first and subsequent lines of therapy is improving outcomes in patients with mutated lung cancer progressing on standard chemotherapy, but a biomarker- or precision-guided approach is needed
Novel ALK-selective TKIs show early efficacy in advanced NSCLC with rare mutations
Further studies are needed to understand the position of the fourth-generation agents NVL-520 and NVL-655 in the treatment paradigm of mutated lung cancer
Further support for durvalumab consolidation as a new standard of care in limited-stage SCLC
Subgroup analyses from the ADRIATIC study support previous practice-changing findings
Role of female leaders in addressing gender gaps in oncology
ESMO Women for Oncology Award Recipient Prof. Myung Hu Ahn discusses gender equity in lung cancer research
Cancer in old patients: geriatric assessment and management plays a crucial role to provide personalised care
First recommendations are released from the ESMO/SIOG Cancer in the Elderly Working Group
First-line avimantamab plus lazertinib shows efficacy in patients with high-risk EGFR-mutant advanced NSCLC
In the MARIPOSA study, a significant improvement in progression-free survival was reported in a subgroup with poor prognostic factors